• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Penumbra Inc.

    3/3/25 4:36:50 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001796068
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    PENUMBRA, INC.
    SEC File Number
    001-37557
    Address of Issuer
    One Penumbra Place
    Alameda
    CALIFORNIA
    94502
    Phone
    (510) 748-3200
    Name of Person for Whose Account the Securities are To Be Sold
    LAMBERT SHIU
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    72882083853.403851594903/03/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/15/2021Restricted StockIssuerCheckbox not checked47310/15/2021Not Applicable
    Common11/15/2021Restricted StockIssuerCheckbox not checked24511/15/2021Not Applicable
    Common02/09/2018Restricted StockIssuerCheckbox not checked29502/09/2018Not Applicable
    Common11/15/2019Restricted StockIssuerCheckbox not checked17711/15/2019Not Applicable
    Common11/15/2018Restricted StockIssuerCheckbox not checked24511/15/2018Not Applicable
    Common02/09/2020Restricted StockIssuerCheckbox not checked29602/09/2020Not Applicable
    Common11/15/2020Restricted StockIssuerCheckbox not checked17711/15/2020Not Applicable
    Common02/09/2019Restricted StockIssuerCheckbox not checked29502/09/2019Not Applicable
    Common11/15/2023Restricted StockIssuerCheckbox not checked55711/15/2023Not Applicable
    Common08/31/2018Exercised SharesIssuerCheckbox not checked452808/31/2018Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/03/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    11/27/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Lambert M Shiu

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

      ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Event:     BofA Securities 2025 Health Care ConferenceDate:       Tuesday, May 13, 2025Time:      6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com.  The webcast will be available on the company's website for at least two weeks followi

      4/29/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Penumbra Inc.

      10-Q - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:44:54 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:14:52 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Penumbra Inc.

      DEFA14A - Penumbra Inc (0001321732) (Filer)

      4/16/25 4:29:05 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

      SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

      10/24/22 8:30:00 AM ET
      $BLZE
      $GSIT
      $PEN
      Computer Software: Prepackaged Software
      Technology
      Semiconductors
      Medical/Dental Instruments

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,818,006 worth of shares (16,650 units at $289.37), increasing direct ownership by 18% to 75,237 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/9/25 7:35:53 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Yuen Maggie exercised 900 shares at a strike of $158.30 and sold $598,020 worth of shares (2,000 units at $299.01), decreasing direct ownership by 7% to 14,857 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/6/25 7:30:45 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Director Bose Arani sold $3,584,775 worth of shares (12,000 units at $298.73), decreasing direct ownership by 4% to 302,819 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      4/29/25 7:34:22 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Penumbra Inc.

      SC 13G - Penumbra Inc (0001321732) (Subject)

      2/14/24 10:03:02 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Penumbra with a new price target

      UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

      1/21/25 8:26:37 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Penumbra with a new price target

      Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

      12/17/24 7:54:12 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian governme

      2/18/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care